Every 8-K that Colgate-Palmolive Company (CL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CL filings page.
Colgate-Palmolive Company reported second quarter 2026 net sales of $5,361 million, up 4.9% from 2025, with organic sales growth of 2.4%. GAAP diluted EPS decreased 5% to $0.86, while non-GAAP Base Business EPS rose 8% to $0.99. GAAP and Base Business gross profit margin improved 140 basis points to 61.5%. GAAP operating profit was $1,016 million (down 6%), but non-GAAP operating profit increased 5% to $1,145 million, with a 21.4% margin.
For the first six months of 2026, net sales were $10,686 million and net income attributable to Colgate-Palmolive was $1,339 million, with diluted EPS of $1.67. Net cash provided by operations was $1,742 million, generating free cash flow before dividends of $1,476 million. Total debt was $7,857 million, with debt less cash, cash equivalents and marketable securities of $6,404 million. The company reported year-to-date global market shares of 41.3% in toothpaste and 32.7% in manual toothbrushes. For full year 2026, Colgate-Palmolive still expects net sales up 2% to 6% and organic sales growth of 1% to 4%, and now expects gross profit margin to be roughly flat on both GAAP and Base Business bases, with GAAP EPS still projected to grow at a double-digit rate and Base Business EPS at a mid-single-digit rate.
Colgate-Palmolive Company held its Annual Meeting of Stockholders on May 8, 2026. Stockholders elected ten directors, including Noel Wallace and nine other nominees, each receiving several hundred million votes in favor, with broker non-votes recorded on the election items.
Stockholders ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 647,385,500 votes for and 53,015,911 against. A non-binding advisory vote on executive compensation was approved, with 591,185,556 votes for and 43,039,011 against.
Two stockholder proposals were not approved. A proposal titled “Remove DEI from Board Candidate Considerations” received 14,002,273 votes for and 618,251,142 against. A proposal titled “Independent Board Chairman” received 182,439,869 votes for and 452,415,385 against.
Colgate-Palmolive Company reported mixed first quarter 2026 results and expanded its Strategic Growth and Productivity Program. Net sales rose to $5,324 million, up 8.4% from $4,911 million, with organic sales up 2.9%. GAAP diluted EPS declined 6% to $0.80, while Base Business diluted EPS increased 7% to $0.97. Operating profit on a GAAP basis fell 10% to $964 million, but Base Business operating profit grew 4% to $1,134 million. Net cash provided by operations was $747 million, producing free cash flow before dividends of $609 million.
The Board approved an expansion of the Strategic Growth and Productivity Program, now expected to generate cumulative pre-tax charges of $350 million to $550 million, up from $200 million to $300 million, with 80% to 90% of these charges in cash and substantially all incurred by December 31, 2028. The program targets organizational changes and supply chain optimization across all regions and businesses. Colgate maintained its 2026 sales and EPS guidance but now expects gross profit margin to be down on both GAAP and Base Business bases.
Colgate-Palmolive Company is planning a legal leadership transition. Jennifer M. Daniels, Chief Legal Officer and Secretary since 2014, has informed the company of her intention to retire in 2026. On April 8, 2026, the Board elected Betsy Fishbone, currently Executive Vice President and Deputy Chief Legal Officer, to become Chief Legal Officer and Secretary effective June 1, 2026. On the same date, the Board elected Ms. Daniels as Vice Chair of the company, also effective June 1, 2026, to support an orderly handover of her responsibilities to Ms. Fishbone.
Colgate-Palmolive Company is changing how it reports its business segments as part of its Strategic Growth and Productivity Program. Effective for the quarter ending March 31, 2026, the former Europe and Africa/Eurasia segments (excluding Russia and Belarus) and the Skin Health business will be combined into a new Europe, Middle East and Africa reportable segment. Russia and Belarus will now be included in the Asia Pacific reportable segment.
The company states this realignment does not affect its historical consolidated results of operations, financial position or cash flows. For consistency, it has recast historical geographic segment information. In the recast data, total net sales were $20,382 million with operating profit of $3,306 million for the year ended December 31, 2025, and total net sales were $19,457 million with operating profit of $3,984 million for the year ended December 31, 2023.
Colgate-Palmolive Company reported board changes centered on leadership expertise. On March 12, 2026, the board elected Christopher S. Boerner, Ph.D., Board Chair and Chief Executive Officer of Bristol-Myers Squibb Company, as a director effective March 15, 2026. He will be compensated under Colgate-Palmolive’s existing non-employee director compensation program as described in its March 26, 2025 proxy statement.
On the same date, director Steven A. Cahillane informed the board that he will not stand for reelection at the Annual Meeting of Stockholders scheduled for May 8, 2026, due to the demands of his new role as Chief Executive Officer of The Kraft Heinz Company.
Colgate-Palmolive Company filed a current report to furnish a press release announcing its earnings for the quarter and year ended December 31, 2025. The press release, dated January 30, 2026, is attached as Exhibit 99 and provides the company’s detailed financial results.
The earnings information is provided under Item 2.02 as furnished, not filed, which limits its use under certain securities law provisions. The filing also includes an Inline XBRL cover page data file as Exhibit 104.
Colgate-Palmolive Company announced the issuance and sale of €600,000,000 aggregate principal amount of its 3.250% Senior Notes due 2035. The company entered into an underwriting agreement on November 3, 2025 with Barclays Bank PLC and Banco Bilbao Vizcaya Argentaria, S.A., acting as representatives of the underwriters.
The notes were offered under Colgate-Palmolive’s automatic shelf registration statement on Form S-3 (File No. 333-275201), with a Prospectus Supplement dated November 3, 2025 and filed November 5, 2025. The notes were issued on November 10, 2025 under the existing Indenture dated November 15, 1992 with The Bank of New York Mellon as trustee. The underwriting agreement, the Indenture, and the form of the notes were filed as exhibits.
Colgate-Palmolive (CL) filed an 8-K stating it furnished a press release announcing earnings for the quarter ended September 30, 2025, and outlined expected costs for a new three-year Strategic Growth and Productivity Program.
The program is estimated to result in cumulative pre-tax charges of $200 to $300 million. The Company expects 65% to 75% to be employee-related costs (severance and other termination benefits) and 25% to 35% to be asset-related and other charges (accelerated depreciation, asset write-offs, contract termination and other exit costs). It estimates 75% to 85% of these charges will require cash expenditures, with substantially all charges incurred by December 31, 2028. The Company indicates the charges will relate to initiatives across regions and businesses: North America (15% to 20%), Latin America (15% to 20%), Europe (10% to 15%), Asia Pacific (10% to 15%), Africa/Eurasia (5% to 10%), Hill’s Pet Nutrition (10% to 15%), and Corporate (10% to 15%).
Colgate-Palmolive (NYSE: CL) filed an 8-K dated 1 Aug 2025 reporting two material items.
- Item 2.02 – Earnings release: The Q2-25 earnings press release was furnished as Exhibit 99; the filing itself contains no revenue, EPS or margin data and is not deemed “filed” for Exchange Act liability purposes.
- Item 2.05 – Three-year Productivity Program: Approved 31 Jul 2025, the initiative is intended to support the company’s 2030 strategy by streamlining the organisational structure and optimising the global supply chain. Management expects cumulative pre-tax charges of $200-$300 million, classified in the Corporate segment, with substantially all costs recognised by 31 Dec 2028.
The company cautions that forward-looking statements about timing and amount of charges may differ materially from current projections. No cost-savings targets, head-count impacts or earnings guidance were disclosed.